70
Participants
Start Date
April 30, 2013
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
Liraglutide
Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Sitagliptin
Sitagliptin 100mg will be given once daily for 12 weeks.
Exenatide
Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
Liraglutide placebo
Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
Sitagliptin placebo
Sitagliptin-placebo be given once daily for 12 weeks.
Exenatide placebo
Exenatide-placebo (saline) will be administered intravenously
L-NMMA
VU University Medical Center, Amsterdam
EU FP7: SAFEGUARD consortium
UNKNOWN
Amsterdam UMC, location VUmc
OTHER